Model Comparison
How NANOSTACKS™ Compares to Other In Vitro Models
Including Transwells, organoids, and organ-on-chip systems
A comprehensive comparison of all major in vitro model systems — examining where each approach provides scientific value for drug safety, toxicology, and pharmacology research.
On this page
Overview
Four Approaches to In Vitro Modeling
Transwells, organoids, organ-on-chip systems, and NANOSTACKS™ represent four distinct approaches to in vitro modeling, each optimised for different levels of biological complexity, experimental control, and application. Selecting the right model depends on your experimental question, available infrastructure, and the physiological relevance required.
Transwells
Simple, 2D barrier models. High reproducibility, low complexity. Limited to two compartments and static conditions.
Organoids
Biologically complex 3D self-organising structures. High disease relevance but variable and difficult to standardise.
Organ-on-Chip
Microfluidic chips with active flow. Dynamic but require specialist hardware, pumps, and expertise.
NANOSTACKS™
Modular, controlled, scalable multi-organ systems. Combines physiological relevance with standard lab compatibility.
Side-by-Side
Full Comparison Table
| Feature | Transwell | Organoid | Organ-on-Chip | NANOSTACKS™ |
|---|---|---|---|---|
| Tissue architecture | Single monolayer | Self-organised 3D | Single cell layer (chip-dependent) | Defined multi-layer |
| Flow / shear | Static | Static (typically) | Microfluidic pump-driven | Orbital shaking — physiological shear |
| Cell type control | Defined | Variable / stochastic | Defined | Precisely defined |
| Reproducibility | High | Moderate–Low | Moderate | High |
| Multi-organ capability | No | Difficult | Limited — chip-specific | Yes — validated configurations |
| Assay compatibility | High | Moderate | Low–Moderate | High — standard plate format |
| Throughput | High | Low–Moderate | Low | Medium–High |
| Specialist equipment | None | Minimal | Pumps, controllers, chips | None — orbital shaker only |
| Setup complexity | Low | Moderate | High | Low–Moderate |
| Regulatory precedent | Established | Emerging | Emerging | Emerging (FDA MAct 2.0) |
Visual Comparison
Structural Differences Between Model Systems
These model systems differ primarily in how they control tissue architecture, cell–cell interactions, and exposure to dynamic conditions. NANOSTACKS™ provides a defined, multi-layer microphysiological system that enables controlled cell–cell interaction and dynamic culture conditions, distinguishing it from static Transwell systems, self-organised organoids, and hardware-intensive organ-on-chip platforms.
Transwell
Simple, 2D barrier models
Organoid
3D but variable, low control
Organ-on-Chip
Dynamic but complex infrastructure
NANOSTACKS™
Modular, controlled, scalable multi-organ systems
Fig. Schematic comparison of in vitro model architectures highlighting differences in tissue organisation, flow dynamics, and experimental control. Not to scale.
Transwell Systems
Transwells
Simple, 2D barrier models
Transwell inserts (also referred to as permeable membrane cell culture inserts) are widely used for two-compartment culture models and have an extensive history in barrier integrity, drug transport, and co-culture studies.
Strengths
- Simple, low-cost, and widely available format
- Well-established regulatory precedent for barrier and transport studies
- High reproducibility within controlled experiments
- Directly compatible with standard laboratory workflows
Limitations
- Static culture — no physiological shear stress or dynamic flow
- Limited to two compartments — insufficient for multi-tissue systems
- Cannot model complex multi-layer organ architectures
- Cells in static culture tend to dedifferentiate over time
- Not suitable for systemic multi-organ pharmacokinetic studies
Organoid Systems
Organoids
3D but variable, low experimental control
Organoids are self-organising three-dimensional structures derived from stem cells or tissue progenitors. They spontaneously develop organ-like architectures and have been applied to disease modelling, developmental biology, and personalised medicine research.
Strengths
- Self-organisation produces complex, tissue-like 3D structures
- Suitable for disease modelling and developmental studies
- Can be derived from patient-specific iPSCs for personalised applications
- Captures organ architecture not present in 2D cultures
Limitations
- High batch-to-batch variability reduces reproducibility
- Difficult to control exact cell-type composition
- Imaging and assay access limited by the 3D structure
- Not compatible with standard plate-reader or MEA formats
- Challenging to integrate into multi-organ systems
- Typically require Matrigel and specialist growth factors
Organ-on-Chip Systems
Organ-on-Chip
Dynamic but complex infrastructure and low throughput
Organ-on-chip platforms use photolithography-fabricated microfluidic chips with integrated channels, pumps, and controllers to recreate dynamic flow across cell layers. They offer fine control over mechanical and chemical stimuli but present significant adoption barriers for routine pharmaceutical use.
Strengths
- Precise control over fluid flow and mechanical stimuli
- Can recreate tissue-specific shear stress conditions
- Enables real-time monitoring of cellular responses
- Suitable for complex vascular and lung barrier modelling
Limitations
- Requires dedicated pumps, tubing, and microfluidic controllers
- Proprietary chip procurement — high cost per experiment
- Steep learning curve for standard cell biology labs
- Low throughput — typically single-chip experiments
- Limited compatibility with standard assay formats
- Difficult to scale for pharmaceutical screening programs
NANOSTACKS™
NANOSTACKS™
Modular, controlled, scalable multi-organ systems
NANOSTACKS™ occupies a distinct position between these systems. It provides the reproducibility and assay compatibility of Transwells, adds multi-layer multicellular complexity beyond organoids, and delivers physiological flow conditions without the infrastructure burden of organ-on-chip. All in a standard 24-well plate format.
NANOSTACKS™ is well-suited when you need
- Quantitative, reproducible toxicology data across multiple cell types
- Physiologically relevant flow conditions without microfluidic hardware
- Multi-organ or multi-tissue studies in standard plate format
- MEA electrophysiology, imaging, or metabolomics readouts
- Extended culture duration (14–28+ days)
- Scalable studies compatible with standard lab infrastructure
Decision Guide
When to Use Each Model
Transwell
Simple, 2D barrier models
- Simple two-compartment transport or permeability studies
- Established barrier integrity assays (TEER)
- Budget-constrained screening with basic co-culture requirements
Organoid
3D but variable, low control
- Patient-derived disease modelling
- Developmental biology and stem cell research
- Applications where tissue self-organisation is the primary readout
Organ-on-Chip
Dynamic but complex infrastructure
- Studies requiring precise, pump-driven flow profiles
- Single-organ vascular or lung barrier research
- Labs with dedicated microfluidics infrastructure
NANOSTACKS™
Modular, controlled, scalable, human-relevant
- Quantitative drug safety and DILI studies with multicellular human relevance
- Functional neurotoxicity with MEA readouts
- Multi-organ pharmacokinetic and IVIVE studies
- Studies requiring high reproducibility, defined cell composition, and assay compatibility
- Compatible with standard lab workflows (no pumps or complex microfluidics required)
Summary
Summary
No single in vitro model is universally optimal. Transwells remain useful for simple, well-established transport and barrier assays. Organoids offer unique advantages for disease modelling and patient-derived applications where biological self-organisation is key. Organ-on-chip systems deliver fine flow control but demand significant infrastructure. NANOSTACKS™ provides the best balance for quantitative toxicology, drug safety screening, and multi-organ studies where reproducibility, defined cell composition, physiological flow, and assay compatibility are priorities — without the complexity of microfluidics.
For detailed experimental design guidance, consult the FAQ or contact the Revivocell scientific team.
Discuss the right model for your study
Our scientists can help you select and configure the appropriate model system for your experimental objectives.